News

The Healthcare & Science business of Thomson Reuters has announced that it is joining Research4Life to provide the developing world with access to critical scientific research. Special editions

Schering-Plough has triggered its pre-existing option to extend the current collaboration with MorphoSys for another year. Schering-Plough will have continued access to MorphoSys’s proprietary antibody HuCAL GOLD, and

CeNeRx has received the rights to develop and market a novel agent for the prevention and treatment of neuropathies and neurodegenerative disorders. The drug candidate, CXB909 is a

Eli Lilly and Maryland-based MacroGenics have declared that the Protege trial has achieved its targeted patient enrollment. The Protege trial is a randomized, double-blind, multi-center, multi-national, 4-arm, controlled

Matrixx Initiatives has confirmed that it has received a warning letter from FDA about two of its 19 existing Zicam products – Zicam Cold Remedy Nasal Gel and

Abbott has announced the initiation of Spirit Prime, a clinical trial to study the performance of the next-generation Xience Prime Everolimus Eluting Coronary Stent System, for the treatment

Switzerland-based Lonza and US-based Elusys have entered into an agreement to produce Anthim. Anthim is a therapeutic monoclonal antibody in late stage of development for the treatment of

CeNeRx has announced the completion of $9 million financing. The financing includes a $5 million credit facility from MidCap Financial, and an additional $4 million invested by current

Pennsylvania-based Three Rivers Pharmaceuticals has announced positive results from phase-III direct trial of once-daily Infergen with Ribavirin in Hepatitis C virus treatment failures. Among participants who failed initial